USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

Dr. Volker Gerdts, VIDO Director Dr. Volker Gerdts, VIDO Director

USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization (VIDO) at the University of Saskatchewan (USask).

“We are excited to start clinical trials,” said VIDO Director Dr. Volker Gerdts. “Our team has worked hard to advance the development of this vaccine to help combat the COVID-19 pandemic.” 

The trial was designed as a combined Phase 1/Phase 2 study. Phase 1 will vaccinate 108 healthy volunteers in a placebo-controlled study at the Canadian Center for Vaccinology (CCfV) in Halifax. Two doses will be administered to each volunteer 28 days apart....

https://www.vido.org/news/usask%E2%80%99s-vido-begins-covid-19-vaccine-clinical-trials-at-ccfv